Cervical intraepithelial neoplasia (CIN) is caused by human papillomavirus (HPV) infection and is the precursor to cervical carcinoma. The completion of the HPV productive life cycle depends on the expression of viral proteins. Initiation of the viral productive replication requires expression of the E2 viral protein that cooperates with the E1 viral DNA helicase. A […]
| Institute |
|---|
| A*STAR Accelerate Technologies Pte Ltd |
| Cat. #: | 153202 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Gynaecologic cancer |
| Research Fields: | Cancer;Cell biology;Microbiology |
| Application: | IHC ; WB |
| Target: | HPV16E2 |
| Reactivity: | Human |
| Clone: | HPV16E2 |
| Host: | Rabbit |
| Class: | Polyclonal |
| Alternate name: | Human papillomavirus type 16; Regulatory protein E2 |
|---|---|
| Product description: | Cervical intraepithelial neoplasia (CIN) is caused by human papillomavirus (HPV) infection and is the precursor to cervical carcinoma. The completion of the HPV productive life cycle depends on the expression of viral proteins. Initiation of the viral productive replication requires expression of the E2 viral protein that cooperates with the E1 viral DNA helicase. A novel and important role for the HPV16-E2 protein in controlling host cell cycle during malignant transformation was recently revealed. Xells expressing HPV16-E2 in vitro were arrested in prophase alongside activation of a sustained DDR signal. In vivo, HPV16-E2 protein is present in cells that express both mitotic and DDR signals specifically in CIN3 lesions, immediate precursors of cancer, suggesting that E2 may be one of the drivers of genomic instability and carcinogenesis in vivo. |
| Conjugation: | Unconjugated |
| Immunogen: | GST-HPV16 E2 (209365) |
| Immunogen Uniprot ID: | TBC |
| Target background: | Cervical intraepithelial neoplasia (CIN) is caused by human papillomavirus (HPV) infection and is the precursor to cervical carcinoma. The completion of the HPV productive life cycle depends on the expression of viral proteins. Initiation of the viral productive replication requires expression of the E2 viral protein that cooperates with the E1 viral DNA helicase. A novel and important role for the HPV16-E2 protein in controlling host cell cycle during malignant transformation was recently revealed. Xells expressing HPV16-E2 in vitro were arrested in prophase alongside activation of a sustained DDR signal. In vivo, HPV16-E2 protein is present in cells that express both mitotic and DDR signals specifically in CIN3 lesions, immediate precursors of cancer, suggesting that E2 may be one of the drivers of genomic instability and carcinogenesis in vivo. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | Whole serum |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Xue et al. 2015. Oncotarget. 6(33):34979-91. PMID: 26474276. HPV16-E2 induces prophase arrest and activates the cellular DNA damage response in vitro and in precursor lesions of cervical carcinoma. Xue et al. 2010. Cancer Res. 70(13):5316-25. PMID: 20530671. HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.